From the molecule to the clinic--inhibiting HER2 to treat breast cancer

N Engl J Med. 2001 Mar 15;344(11):841-2. doi: 10.1056/NEJM200103153441110.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Female
  • Heart Diseases / chemically induced
  • Humans
  • Neoplasm Metastasis
  • Receptor, ErbB-2 / immunology*
  • Receptor, ErbB-2 / metabolism
  • Survival Analysis
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Receptor, ErbB-2
  • Trastuzumab